Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17094951 | 1.00 | CYP2C19 (0.57) | CYP2C19CA1CA2MEP1BAKR1C3 | |
| SCHEMBL26144924 | 0.88 | CYP2C19 (0.57) | CYP2C19CA1CA2MEP1BAKR1C3 | |
| SCHEMBL13543487 | 0.88 | CA1 (0.62) | CYP2C19CA1CA2MEP1BAKR1C3 | |
| SCHEMBL26144925 | 0.86 | CYP2C19 (0.52) | CYP2C19CA1CA2MEP1BAKR1C3 | |
| SCHEMBL26144930 | 0.85 | CYP2C19 (0.57) | CYP2C19CA1CA2MEP1BAKR1C3 | |
| SCHEMBL26144931 | 0.84 | CA1 (0.57) | CYP2C19CA1CA2MEP1BAKR1C3 | |
| SCHEMBL16197361 | 0.81 | TDP1 (0.55) | CA2MEP1BSMN1; SMN2 | |
| SCHEMBL18740475 | 0.81 | POLB (0.56) | CYP2C19CA1CA2AKR1C3F2 | |
| SCHEMBL18740472 | 0.81 | POLB (0.56) | CYP2C19CA1CA2AKR1C3F2 | |
| SCHEMBL3971671 | 0.81 | SMN1; SMN2 (0.74) | CYP2C19CA2SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-113444063-A | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-113321632-A | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-08-31 | — | — | CN | disclosed |
| EP-2890375-B1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-07-28 | — | — | EP | disclosed |
| US-10995064-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2021-05-04 | — | — | US | disclosed |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210024462-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-01-28 | — | — | US | disclosed |
| EP-1789390-B1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH INC (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110092461-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | CURIS ROYALTY LLC | 2011-04-21 | — | — | US | disclosed |
| US-7888364-B2 | Pyridyl inhibitors of hedgehog signalling | CURIS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| EP-2271642-A2 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | Genentech, Inc. (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20090281089-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009126863-A2 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| CN-101072755-A | Pyridyl inhibitors of Hedgehog signaling | GENENTECH INC (US) | 2007-11-14 | — | — | CN | disclosed |
| EP-1789390-A2 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | Genentech, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060063779-A1 | Pyridyl inhibitors of hedgehog signalling | CURIS ROYALTY LLC | 2006-03-23 | — | — | US | disclosed |
| WO-2006028958-A2 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CYP2C19 4731/4885CA1 4396/4885CA2 3856/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CYP2C19 4721/4885CA1 4482/4885CA2 3954/4885 |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | CYP2C19 4696/4885CA1 3796/4885CA2 3528/4885 |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CYP2C19 4731/4885CA1 4396/4885CA2 3856/4885 |
| US-20090281089-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CYP2C19 4731/4885CA1 4396/4885CA2 3856/4885 |
| US-10995064-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | SULT2A1, HCCS, SULT1A1 | CYP2C19 447/4885CA1 4327/4885CA2 3623/4885 |
| US-20060063779-A1 | Pyridyl inhibitors of hedgehog signalling | SHH, GLI1, SMO | CYP2C19 4731/4885CA1 4396/4885CA2 3856/4885 |
| US-20110092461-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | CYP2C19 4731/4885CA1 4396/4885CA2 3856/4885 |
| US-20210024462-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | CYP2C19 447/4885CA1 4327/4885CA2 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.